Anne-Marie Faucher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anne-Marie Faucher has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Christian Brochu
3 shared publications- Jean-Simon Duceppe
ProMetic BioSciences Inc., 500 Boulevard Cartier Ouest, Bureau 150, Laval, Québec, Canada H7V 5B7
2 shared publications Bruno Haché
1 shared publicationBruno Simoneau
Chemistry Department, Boehringer Ingelheim (Canada) Ltd., Research and Development, 2100 Cunard Street, Laval, (Québec) Canada H7S 2G5
1 shared publicationChantal Grand-Maître
Boehringer Ingelheim (Canada) Ltd., Research and Development, 2100 Cunard Street, Laval (Québec), Canada, H7S 2G5
1 shared publicationElise Ghiro
Chemistry Department, Boehringer Ingelheim (Canada) Ltd., Research and Development, 2100 Cunard Street, Laval, (Québec) Canada H7S 2G5
1 shared publication
Latest Publications
- 4 July 2006
- Published by Georg Thieme Verlag KG in Synthesis
- Vol. 2006 (15) , 2563-2567
Practical Synthesis of 2-(2-Isopropylaminothiazol-4-yl)-7-methoxy-1H-quinolin-4-one: Key Intermediate for the Synthesis of Potent HCV NS3 Protease Inhibitor BILN 2061
Herein we describe the development of an efficient, safe and practical process for the synthesis of 7-methoxy-2-(2-amino-4-thiazolyl)quinoline. Our new process allowed for a more convergent approach and eliminates the use of potentially dangerous reagents such as diazomethane used in the previous discovery approach.
- 4 July 2006
- Published by Georg Thieme Verlag KG in Synthesis
- Vol. 2006 (15) , 2563-2567
Practical Synthesis of 2-(2-Isopropylaminothiazol-4-yl)-7-methoxy-1H-quinolin-4-one: Key Intermediate for the Synthesis of Potent HCV NS3 Protease Inhibitor BILN 2061
Herein we describe the development of an efficient, safe and practical process for the synthesis of 7-methoxy-2-(2-amino-4-thiazolyl)quinoline. Our new process allowed for a more convergent approach and eliminates the use of potentially dangerous reagents such as diazomethane used in the previous discovery approach.
- 21 July 2004
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 6 (17) , 2901-2904
Synthesis of BILN 2061, an HCV NS3 Protease Inhibitor with Proven Antiviral Effect in Humans
The synthesis of BILN 2061, an NS3 protease inhibitor with proven antiviral effect in humans, was accomplished in a convergent manner from four building blocks. The procedure described here was suitable for the preparation of multigram quantities of BILN 2061 for preclinical pharmacological evaluation.
- 21 July 2004
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 6 (17) , 2901-2904
Synthesis of BILN 2061, an HCV NS3 Protease Inhibitor with Proven Antiviral Effect in Humans
The synthesis of BILN 2061, an NS3 protease inhibitor with proven antiviral effect in humans, was accomplished in a convergent manner from four building blocks. The procedure described here was suitable for the preparation of multigram quantities of BILN 2061 for preclinical pharmacological evaluation.
- 9 December 2003
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 47 (1) , 18-21
Discovery of Small-Molecule Inhibitors of the ATPase Activity of Human Papillomavirus E1 Helicase
The Boehringer Ingelheim compound collection was screened for inhibitors of the ATPase activity of human papillomavirus E1 helicase to develop antiviral agents that inhibit human papillomavirus (HPV) DNA replication. This screen led to the discovery of (biphenyl-4-sulfonyl)acetic acid 1, which inhibits the ATPase activity of HPV type 6 E1 helicase with a low micromolar IC50 value. A hit-to-lead exercise rapidly converted 1 into a low nanomolar lead series.
- 9 December 2003
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 47 (1) , 18-21
Discovery of Small-Molecule Inhibitors of the ATPase Activity of Human Papillomavirus E1 Helicase
The Boehringer Ingelheim compound collection was screened for inhibitors of the ATPase activity of human papillomavirus E1 helicase to develop antiviral agents that inhibit human papillomavirus (HPV) DNA replication. This screen led to the discovery of (biphenyl-4-sulfonyl)acetic acid 1, which inhibits the ATPase activity of HPV type 6 E1 helicase with a low micromolar IC50 value. A hit-to-lead exercise rapidly converted 1 into a low nanomolar lead series.